1061 — Essex Bio-Technology Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$1.31bn
- HK$1.09bn
- HK$1.71bn
- 94
- 93
- 31
- 89
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 352 | 251 | 394 | 260 | 346 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -7.21 | -13.2 | 33 | 37.6 | 3.63 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -139 | 34.4 | -50.8 | 43.3 | -70 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 233 | 299 | 409 | 383 | 339 |
Capital Expenditures | -176 | -330 | -255 | -283 | -128 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -3.5 | -13.3 | -25.2 | -19.1 | 73.7 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -180 | -343 | -280 | -302 | -54.3 |
Financing Cash Flow Items | -5.58 | -8.64 | -12.3 | -15.7 | -15.9 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 113 | 149 | -73.1 | -169 | -310 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 162 | 126 | 71.6 | -128 | -33.6 |